Literature DB >> 24270346

T cells and costimulation in cancer.

Tomasz Maj1, Shuang Wei, Ted Welling, Weiping Zou.   

Abstract

Optimal T cell response is dependent not only on T cell receptor activation, but also on additional signaling from coreceptors. The main coreceptors include B7 and tumor necrosis factor family members. They exert costimulatory or coinhibitory effects, and their balance determines the fate of T cell response. In normal conditions, costimulators facilitate the development of protective immune response, whereas coinhibitors dampen inflammation to avoid organ/tissue damage from excessive immune reaction. In the tumor microenvironment, the balance is garbled: inhibitory pathways predominate, and T cell response is impaired. The importance of cosignaling in the tumor immune response has been experimentally and clinically demonstrated. New therapeutic strategies targeting T cell cosignaling, especially coinhibitory molecules, are under active experimental and clinical investigation. This review summarizes the functions of main T cell cosignaling axes and discusses their clinical application.

Entities:  

Mesh:

Year:  2013        PMID: 24270346     DOI: 10.1097/PPO.0000000000000002

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  11 in total

Review 1.  Checkpoint Inhibitors and Their Application in Breast Cancer.

Authors:  Davide Bedognetti; Cristina Maccalli; Salha B J Al Bader; Francesco M Marincola; Barbara Seliger
Journal:  Breast Care (Basel)       Date:  2016-04-26       Impact factor: 2.860

2.  B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.

Authors:  Ruishu Deng; Kaniel Cassady; Xiaofan Li; Sheng Yao; Mingfeng Zhang; Jeremy Racine; Jeffrey Lin; Lieping Chen; Defu Zeng
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

3.  Cancer cell-expressed B7-H3 regulates the differentiation of tumor-associated macrophages in human colorectal carcinoma.

Authors:  Yong Mao; Lujun Chen; Fengming Wang; Dawei Zhu; Xiaosong Ge; Dong Hua; Jing Sun
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

Review 4.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

Review 5.  T-cell exhaustion in the tumor microenvironment.

Authors:  Y Jiang; Y Li; B Zhu
Journal:  Cell Death Dis       Date:  2015-06-18       Impact factor: 8.469

Review 6.  Combinations of immunotherapy and radiation in cancer therapy.

Authors:  Ralph E Vatner; Benjamin T Cooper; Claire Vanpouille-Box; Sandra Demaria; Silvia C Formenti
Journal:  Front Oncol       Date:  2014-11-28       Impact factor: 6.244

Review 7.  Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?

Authors:  Angela Toss; Marta Venturelli; Chiara Peterle; Federico Piacentini; Stefano Cascinu; Laura Cortesi
Journal:  Int J Mol Sci       Date:  2017-01-04       Impact factor: 5.923

8.  Tim-3 and PD-1 regulate CD8+ T cell function to maintain early pregnancy in mice.

Authors:  Yuan-Yuan Xu; Song-Cun Wang; Yi-Kong Lin; Da-Jin Li; Mei-Rong DU
Journal:  J Reprod Dev       Date:  2017-03-23       Impact factor: 2.214

Review 9.  Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.

Authors:  Reginald M Gorczynski; Fang Zhu
Journal:  Cancer Manag Res       Date:  2017-11-13       Impact factor: 3.989

Review 10.  Fates of CD8+ T cells in Tumor Microenvironment.

Authors:  Nomathamsanqa Resegofetse Maimela; Shasha Liu; Yi Zhang
Journal:  Comput Struct Biotechnol J       Date:  2018-11-22       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.